Randox Pharma
Services was founded with such a translational mission, and for 30 years has
been carrying out R&D, custom assay development and supplying diagnostic solutions;
all underpinned by a strong commitment to collaborate with leading academic research
centres and pharmaceutical companies globally.
In recognition of the vital role
biomarkers play in
translational medicine, Randox Pharma Services supply an unrivalled range of
single analyte and multiplex diagnostic kits direct to end user laboratories. Indeed, even kits produced primarily for
research come under the same scrutiny as any commercial IVD assay i.e. imprecision
less than 10%, fully optimised to eliminate cross-reactivity and non-specific
binding to name just a few of our stringent QA processes.
As a private
company Randox Pharma Services can be flexible and are swift to focus our
significant in-house resources and expertise towards any pressing healthcare
need; with a particular focus on oncology, infectious disease and metabolic
disorders.
To enable this Randox have developed
Biochip Array
Technology, a multiplex technology which allows the simultaneous detection of
multiple biomarkers from a single patient sample. Given the increased value of
multiple biomarkers to improve patient diagnosis, such a technology is the
ideal ‘target platform' for translational science. Already arrays have been developed which are
applicable to a broad range of therapeutic areas, with applications including
multiplex immunoassays and nucleic acid based SNP, mutation, gene expression
and pathogen detection arrays.
Randox Pharma Services also offer over 130 enzymatic,
substrate and immunoturbidimetric assays on our class-leading range of
RX
Series chemistry analysers which provide quality results at every phase from
pre-clinical testing through to the clinic.
With robust, fit-for-purpose assays a pre-requisite for research,
biomarker validation and ultimately translational science, only an established
clinical diagnostic company such as Randox has the scientific and regulatory
experience required. All to meet the pressing need for the more rapid
translation of novel biomarkers to clinical utility.
For more information please visit www.randoxpharmaservices.com or
contact us at pharmaservices@randox.com.
Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!
Request your free copies HERE
Popular this Month
Top 10 most popular articles this month
Today's Picks
Looking for a Supplier?
Search by company or by product
Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.
Lab Bulletin is published by newleaf marketing communications ltd.